


Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis

Graphical abstract



Highlights

- We investigated epidemiology of hepatic steatosis and fibrosis in HIV infected people.
- Hepatic steatosis is common in both HIV mono-infection and HIV/HCV co-infection.
- Hepatic steatosis progresses faster in HIV mono-infection than HIV/HCV co-infection.
- In HIV mono-infection, hepatic steatosis drives fibrosis progression.
- In HIV/HCV co-infection, HCV drives fibrosis progression.

Authors

Thomas Pembroke, Marc Deschenes, Bertrand Lebouché, ..., Costa Pexos, Marina B. Klein, Giada Sebastiani

Correspondence

giada.sebastiani@mcgill.ca
(G. Sebastiani)

Lay summary

Fatty liver is the most frequent liver disease in Western countries. People living with HIV seem at high risk of fatty liver due to frequent metabolic disorders and the long-term effects of antiretroviral therapy. However, due to the invasiveness of liver biopsy, the traditional method of diagnosing fatty liver, there are few data regarding its frequency in people living with HIV. In this study, we used a non-invasive diagnostic tool to analyze the epidemiology of fatty liver in 726 HIV+ patients. We found that fatty liver affects over one-third of people living with HIV. When followed over time, we found that HIV+ patients without HCV co-infection develop fatty liver more frequently than those co-infected with HCV.

Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis

Thomas Pembroke^{1,2}, Marc Deschenes¹, Bertrand Lebouché¹, Amine Benmassaoud¹, Maida Sewitch¹, Peter Ghali¹, Philip Wong¹, Alex Halme¹, Elise Vuille-Lessard¹, Costa Pexos¹, Marina B. Klein¹, Giada Sebastiani^{1,*}

¹Royal Victoria Hospital, McGill University Health Centre, Montreal, QC, Canada; ²School of Medicine, Cardiff University, Cardiff CF14 4XN, UK

Background & Aims: Hepatic steatosis (HS) seems common in patients infected with human immunodeficiency virus (HIV). However, the relative effect of HIV, as well as hepatitis C virus (HCV) in those co-infected, and the influence of HS on liver fibrosis progression are unclear.

Methods: The LIVER disease in HIV (LIVEHIV) is a Canadian prospective cohort study using transient elastography and associated controlled attenuation parameter (CAP) to screen for HS and liver fibrosis, in unselected HIV-infected adults. HS progression was defined as development of any grade HS (CAP \geq 248 dB/m), or transition to severe HS (CAP >292 dB/m), for those with any grade HS at baseline. Fibrosis progression was defined as development of significant liver fibrosis (liver stiffness measurement [LSM] >7.1 kPa), or transition to cirrhosis (LSM >12.5 kPa) for those with significant liver fibrosis at baseline. Cox regression analysis was used to assess predictors of HS and fibrosis progression.

Results: A prospective cohort study was conducted, which included 726 HIV-infected patients (22.7% HCV co-infected). Prevalence of any grade HS did not differ between HIV mono-infected and HIV/HCV co-infected patients (36.1% vs. 38.6%, respectively). 313 patients were followed for a median of 15.4 (interquartile range 8.5–23.0) months. The rate of HS progression was 37.8 (95% confidence interval [CI] 29.2–49.0) and 21.9 (95% CI 15.6–30.7) per 100 person-years in HIV mono-infection and HIV/HCV co-infection, respectively. HCV co-infection was an independent negative predictor of HS progression (adjusted hazard ratio [aHR] 0.50, 95% CI 0.28–0.89). HS predicted liver fibrosis progression in HIV mono-infection (aHR 4.18, 95% CI 1.21–14.5), but not in HIV/HCV co-infection.

Conclusion: HS progresses faster and is associated with liver fibrosis progression in HIV mono-infection but not in HIV/HCV co-infection.

Lay summary: Fatty liver is the most frequent liver disease in Western countries. People living with HIV seem at high risk of

fatty liver due to frequent metabolic disorders and the long-term effects of antiretroviral therapy. However, due to the invasiveness of liver biopsy, the traditional method of diagnosing fatty liver, there are few data regarding its frequency in people living with HIV. In this study, we used a non-invasive diagnostic tool to analyze the epidemiology of fatty liver in 726 HIV+ patients. We found that fatty liver affects over one-third of people living with HIV. When followed over time, we found that HIV+ patients without HCV co-infection develop fatty liver more frequently than those co-infected with HCV.

© 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Hepatic steatosis (HS) is an accumulation of fat in the liver, which may eventually progress to steatohepatitis, a pathologic inflammatory response leading to fibrosis, cirrhosis and liver failure.¹ HS is particularly common in hepatitis C virus (HCV)-infected patients with human immunodeficiency virus (HIV) co-infection, with reported frequencies ranging between 30 and 70%.^{2–6} HCV may induce HS through several mechanisms, including altered lipid metabolism, metabolic risk factors in non-genotype 3 infections and a direct steatogenic effect of HCV genotype 3.⁷ Longitudinal studies are not consistent in implicating HS with faster liver fibrosis progression in HIV/HCV co-infection.^{8,9}

Data on HS in HIV mono-infected patients without HCV are scarce. HIV mono-infection is a risk factor for HS through several postulated mechanisms, including frequent metabolic disorders and the hepatotoxic effect of antiretroviral therapy (ART).³ Moreover, HIV itself is associated with chronic inflammation and immune activation, which further contribute to the development of progressive HS and steatohepatitis.^{10,11} Cross-sectional studies reported a higher prevalence of HS in HIV-infected patients than in the general population.^{2–5} However, a recent report, employing magnetic resonance imaging (MRI) and spectroscopy, suggested that HS is more frequent in uninfected adults than in HIV mono-infected and HIV/HCV co-infected patients.⁷ These contradictory results may derive from different definitions and techniques used

Keywords: HIV mono-infection; HIV/HCV co-infection; Hepatic steatosis; Liver fibrosis; Transient elastography; Liver stiffness; Controlled attenuation parameter; Prevalence; Incidence.

Received 17 February 2017; received in revised form 7 April 2017; accepted 10 May 2017; available online 18 May 2017

* Corresponding author. Address: Royal Victoria Hospital, McGill University Health Centre, Montreal, QC, Canada.

E-mail address: giada.sebastiani@mcgill.ca (G. Sebastiani).



ELSEVIER

Research Article

to diagnose HS, from the cross-sectional study design and the possibility of survivorship bias. Given that HS is a chronic process, longitudinal studies evaluating the dynamics of HS and its effect on liver fibrosis progression in HIV-infected patients, particularly if HIV mono-infected, are needed. However, liver biopsy, the gold standard for HS and fibrosis diagnosis, carries significant risks and is not well suited to large-scale screening programs.¹² Moreover, due to the lack of a clear clinical indication, biopsy-based studies with repeated measures over time are very difficult to conduct, particularly in HIV mono-infected patients, without incurring selection biases.

The introduction of transient elastography (TE), a non-invasive tool which measures liver stiffness as a surrogate of liver fibrosis, provides new possibilities for undertaking this research. The controlled attenuation parameter (CAP) measures the degree of ultrasound attenuation by hepatic fat at the central frequency of the FibroScan (Echosens, Paris, France), simultaneously with liver stiffness measurement (LSM). TE and CAP have been validated for diagnosis of HS and liver fibrosis in HIV-infected patients.¹³

We have initiated the LIVER disease in HIV (LIVEHIV) Cohort, which is the first North American prospective cohort designed to characterize the epidemiology, dynamics and effect on liver fibrosis of HS in HIV-infected adults undergoing a routine screening program with TE and associated CAP. The aims of the present study were: (i) To investigate prevalence and associated cofactors of HS and significant liver fibrosis; and (ii) To investigate incidence and predictors of HS and liver fibrosis progression in HIV-infected patients, with or without HCV co-infection.

Patients and methods

Study design and population

The LIVEHIV Cohort is a prospective routine screening program for HS and liver fibrosis established in September 2013 at McGill University Health Centre (MUHC), Montreal, Canada. As of September 2016, 1,173 patients have been enrolled in the LIVEHIV Cohort and underwent screening for liver disease, including HCV and hepatitis B virus (HBV) serology, Alcohol Use Disorders Identification Test (AUDIT-C) questionnaire,¹⁴ and yearly TE with CAP.

The patients included in the present analysis fulfilled the following criteria: 1) age ≥ 18 years; 2) HIV infection, as documented by positive enzyme-linked immunosorbent assay [ELISA] with Western blot confirmation; 3) availability of relevant clinical and biochemical parameters; 4) at least one valid LSM with CAP. Exclusion criteria were: 1) evidence of other liver disease (auto-immune hepatitis, haemochromatosis, Wilson's disease); 2) hazardous alcohol intake (AUDIT-C score ≥ 7 ¹⁴); 3) history or evidence of hepatocellular carcinoma (HCC) or liver transplantation at entry; 4) failure of TE examination or unreliable LSM; 5) contraindications of TE examination (pregnancy; pacemaker insertion). Informed consent was obtained by study participants. The Research Ethics Board of the Research Institute of the MUHC approved the study (code 14-181-BMD), which was conducted according to the Declaration of Helsinki.

Outcome measures and definition of study groups

The primary study outcomes were: (1) prevalence and associated cofactors of any grade HS and significant liver fibrosis; (2) incidence and predictors of HS progression and of liver fibrosis progression. Based on a recent meta-analysis and on previous literature, any grade HS (involving $>10\%$ of hepatocytes) and severe HS (involving $>66\%$ of hepatocytes) were defined as CAP ≥ 248 and CAP >292 decibel per meter (dB/m), respectively.^{15,16} "HS progression" was defined as development of any grade HS, or transition to severe HS for those with CAP <292 dB/m at baseline. "Liver fibrosis progression" was defined as development of significant liver fibrosis (stage F2-4, defined as LSM >7.1 kPa), or transition to cirrhosis (stage F4, defined as LSM >12.5 kPa) for those with LSM >7.1 but <12.5 kPa at baseline.¹⁷ Secondary outcomes were prevalence of severe HS and of cirrhosis.




Fig. 1. Flow chart displaying the selection of study participants and the two study cohorts (prevalence and incidence).

The study cohort was divided into two groups: (1) the prevalence cohort (whole study cohort) of 726 patients with one valid TE examination and the initial study visit between September 2013 and September 2016; (2) the incidence cohort included 313 patients with more than one TE with CAP measurement in the same study period (Fig. 1).

Transient elastography examination

The examination was performed on a 4-h fasting patient. Two experienced operators (>500 examinations before the study) performed 10 valid acquisitions, as previously described.² The standard M probe was used in all patients. The XL probe was used in case of failure with the M probe and if body mass index (BMI) was >30 Kg/m². Examinations with no successful measurements after at least 10 attempts were deemed failures. The following criteria were applied to define the result of the examination as reliable: at least 10 validated measures, an interquartile range (IQR) $<30\%$ of the median, and $>60\%$ success rate.¹⁸ Patients with known risk factors for a false positive LSM were also excluded.¹⁸ The thresholds for liver fibrosis were decreased by -1.5 kPa to interpret the result with the XL probe.¹⁹

Clinical and biological parameters

Relevant data were collected within 3 months from the TE examination. Clinical parameters included age, gender, ethnicity, BMI, history of hypertension or type 2 diabetes mellitus, risk factors for HIV infection, time since HIV diagnosis, exposure to ART. ART drugs were classified as: protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and integrase inhibitors. Biological parameters included: CD4 cell count, HIV viral load (Roche Cobas Amplicor assay, Roche Diagnostics, Hoffmann-La Roche Ltd, lower limit of detection 40 copies/ml), HCV RNA (Roche Cobas Amplicor HCV Test, version 2.0, Roche Diagnostics, Hoffmann-La Roche Ltd), HCV genotype, aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, total cholesterol, low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), and triglycerides. Insulin resistance was determined using the homeostasis model for assessment of insulin resistance (HOMA-IR) index [fasting insulin (mIU/l) X fasting glucose (mmol/l)/22.5].²⁰

Statistical analysis

Baseline (time zero) corresponded to the first visit after September 1st, 2013, when TE examination was performed. We compared characteristics of participants at baseline by outcome status using Student's *t* test for continuous variables and Pearson's χ^2 or Fisher's exact test for categorical variables. Multivariable logistic regression models were built to identify cofactors independently associated with any grade HS and significant liver fibrosis in the prevalence cohort. Results were reported as adjusted odds ratios (aOR) with 95% confidence interval (CI). Patients in the incidence cohort were observed until September 2016 or were censored either when they died or at their last clinic visit. We estimated incidence rates of HS and liver fibrosis progression by dividing the number of participants developing the outcome by the number of person-years (PY) of follow-up. Poisson count models were used to calculate CIs for incidence rates. Kaplan-Meier plots and log-rank tests were used to illustrate time to HS and fibrosis progression. Multivariable time-dependent Cox regression models were constructed to assess predictors of HS and fibrosis progression. Results were reported as adjusted hazard ratios (aHR) with 95% CI. Robust variance estimation was used in all Cox regression analyses to account for the correlation of data contributed by the same participant at multiple visits. Multivariable models included covariates that were determined *a priori* to be clinically important, namely age, Black ethnicity, HCV co-infection status, time since HIV diagnosis, BMI, detectable HIV viral load, detectable HCV RNA, ALT, triglycerides, CAP. A complete case analysis was used for the multivariable models and the percentage of missing data was less than 15%, unless specified. All tests were 2-tailed and with a significance level of $\alpha = 0.05$. Statistical analyses were performed using STATA 13.1 (STATA Corp. LP, College Station, Texas, USA).

Results

After applying exclusion criteria (Fig. 1), 726 HIV-infected patients were included in the prevalence group. The failure rate of TE examination (19.2%) was in line with previous studies.¹⁸ The XL probe was used in 159 (22%) cases, while the standard M probe was applied in the remaining patients. The characteristics of the prevalence (whole) cohort and of the incidence cohort are summarized in Table 1. In the prevalence cohort, alcohol consumption was distributed as follows: 208 (28.7%) were abstinent (AUDIT-C = 0), 359 (49.4%) had low alcohol intake (AUDIT-C = 1–3) and 159 (21.9%) had moderate alcohol intake (AUDIT-C = 4–6). Most patients (92.0%) were on ART. Eleven (1.5%) and 6 (1.9%) patients were HIV/HBV and HIV/HCV/HBV co-infected, respectively. Table S1 depicts the main characteristics of the prevalence (whole) cohort by HCV co-infection status. Among those HIV/HCV co-infected, HCV RNA was detectable in 105 cases (63.6%), while 30 (18.2%) were infected with HCV genotype 3.

Prevalence and associated cofactors of HS and liver fibrosis in the prevalence cohort

The results of the cross-sectional screening phase of the LIVEHIV Cohort are reported in Fig. 2. Overall, 264 (36.4%) and 212 (29.2%) had any grade HS and significant liver fibrosis, respectively. There was no significant difference in the prevalence of any grade HS or severe HS between HIV mono-infected and HIV/HCV co-infected patients. Fig. S1a reports the median CAP value in the prevalence cohort by HCV co-infection status. Table 2 shows the result of a multivariable analysis of cofactors associated with any grade HS and significant liver fibrosis in the prevalence cohort. After adjustments, higher BMI and triglycerides were independently associated with any grade HS. Independent cofactors of significant liver fibrosis were higher BMI, HCV co-infection, longer time since HIV diagnosis, detectable HIV viral load, higher ALT and higher triglycerides. The adjunction of HOMA-IR to the two mod-

els did not change the result and we decided not to include it due to missingness.

Incidence and predictors of HS progression in the incidence cohort

Eighty-one (25.9%) patients from the incidence cohort were excluded from the analysis for having the outcome (severe HS) at baseline. The remaining 232 were followed for a median of 15.4 (IQR 8.5–23.0) months. Fig. S1b reports the median CAP value in the incidence cohort by HCV co-infection status during the follow-up period. Overall, 97 (41.8%) had HS progression, accounting for an incidence rate of 29.7 per 100 PY (95% CI, 24.2–36.5). HIV mono-infected patients had higher rates of HS progression (37.8 per 100 PY, 95% CI 29.2–49.0) compared to HIV/HCV co-infected patients (21.9 per 100 PY, 95% CI 15.6–30.7; Fig. 3a). There was no difference in rates of HS progression by detectable HCV RNA status or HCV genotype 3 (Fig. S2a and S2b, respectively). In order to provide insights into the magnitude of HS dynamics over time, we also looked at HS progression of more than one grade and HS regression. Fig. S3a depicts changes in HS by HCV co-infection status. After adjustments, HS progression was predicted by higher baseline BMI, while anti-HCV positivity was a negative predictor (Table 3). Longer time since HIV diagnosis and higher triglycerides also appeared to be associated, but did not reach statistical significance.

Incidence and predictors of liver fibrosis progression in the incidence cohort

Thirty-nine (12.5%) patients from the incidence cohort were excluded from the analysis for having the outcome (cirrhosis) at baseline. Of the remaining 274 cases, 53 (19.3%) had fibrosis progression, accounting for an incidence rate of 12.7 per 100 PY (95% CI, 9.5–17.1). There was no significant difference in fibrosis progression in patients with and without any grade HS. However, when only HIV mono-infected patients were analyzed, presence vs. absence of any grade HS was associated with higher rates of fibrosis progression (20.4 per 100 PY, 95% CI 13.2–31.6 vs. 5.8 per 100 PY, 95% CI 2.6–13.0; Fig. 3b). Fig. S3b and S3c depict changes in liver fibrosis by HS status in HIV mono-infected and HIV/HCV co-infected patients, respectively. In HIV mono-infected cases, fibrosis progression was independently associated with longer time since HIV diagnosis and any grade HS at baseline (Table 4). In HIV/HCV co-infected patients, detectable HCV RNA and higher ALT were independent predictors of fibrosis progression.

Discussion

Using a large prospective cohort of consecutive HIV-infected patients undergoing a routine screening program, we found that HS diagnosed by TE with CAP is a frequent co-morbidity. Contrary to previous reports, HS was not more prevalent in HIV/HCV co-infected compared to HIV mono-infected patients.^{8,9} Furthermore, HS progresses faster in HIV mono-infected patients than in HIV/HCV co-infected patients, particularly in those who are overweight. This finding underscores the importance of following the evolution of a liver disease over time, which fosters evaluation of incidence, dynamics and predictors, rather than relying

Research Article

Table 1. Characteristics of the prevalence and incidence cohorts.

Variable	Prevalence (whole) cohort (n = 726)	Incidence cohort (n = 313)
Age (years)	50 (42–56)	50 (43–54)
Male gender (%)	547 (75.3)	240 (76.7)
Ethnicity (%)		
White/Caucasian	378 (52.1)	194 (62.0)
Black non-Hispanic	232 (32.0)**	67 (21.4)**
Hispanic	73 (10.1)	25 (8.0)
South Asian	30 (4.1)	15 (4.8)
Other	13 (1.7)	12 (3.8)
MSM (%)	233 (32.1)	104 (33.2)
IDU (%)	98 (13.5)**	78 (24.9)**
HIV endemic country (%)	127 (17.5)	40 (12.8)
Diabetes (%)	182 (25.1)	88 (28.1)
Hypertension (%)	128 (17.6)	59 (18.9)
BMI (Kg/m ²)	25.4 (23.0–28.6)	25.8 (22.6–28.8)
Time since HIV diagnosis (years)	13 (7–20)**	15 (8–22)**
Anti-HCV pos (%)	165 (22.7)**	140 (44.7)**
HBsAg pos (%)	23 (3.2)	15 (4.8)
HIV viral load >40 cp/ml (%)	190 (26.2)*	104 (33.2)*
CD4 count (cells/μl)	544 (373–735)	540 (356–723)
Nadir CD4 count (cells/μl)	197 (96–328)	169 (90–292)
Current ART regimen (%)		
PI	321 (44.2)*	171 (54.6)*
NNRTI	223 (30.7)	94 (30.0)
NRTI	590 (81.3)	269 (85.9)
Integrase inhibitor	202 (27.8)	70 (22.4)
Past stavudine use (%)	166 (22.9)	69 (22.0)
Past didanosine use (%)	91 (12.5)	35 (11.2)
Platelets (10 ⁹ /L)	195 (158–240)	190 (149–235)
AST (IU/L)	27 (21–37)*	31 (23–49)*
ALT (IU/L)	28 (20–44)*	35 (23–58)*
Albumin (g/L)	41 (39–44)	41 (38–43)
HOMA-IR	2.3 (1.5–3.6)	2.4 (1.5–5.6)
Total cholesterol (mmol/L)	4.4 (3.8–5.2)	4.2 (3.7–5.1)
HDL cholesterol (mmol/L)	1.1 (0.9–1.4)	1.1 (0.9–1.3)
LDL cholesterol (mmol/L)	2.5 (1.9–3.2)	2.3 (1.7–3.0)
Triglycerides (mmol/L)	1.4 (0.9–2.2)	1.6 (1.0–2.3)
LSM (kPa)	5.3 (4.1–7.8)*	6.1 (4.7–10.6)*
CAP (dB/m)	233 (196–263)*	246 (208–284)*

Continuous variables are expressed as median (IQR) and categorical variables as numbers (%). * $p < 0.05$; ** $p < 0.001$. The p -values refer to t test or χ^2 test between the prevalence (whole) cohort and the incidence cohort. HOMA-IR was evaluated in 335 patients of the prevalence cohort and in 183 patients of the incidence cohort.

ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMI, body mass index; dB/m, decibels per meter; CAP, controlled association parameter; HCV, hepatitis C virus; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; HOMA-IR, homeostasis model for assessment of insulin resistance; HS, hepatic steatosis; IDU, injection drug use; IU, international unit; LDL, low-density lipoprotein; LSM, liver stiffness measurement; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

on a snapshot to characterize its epidemiology. HS predicted liver fibrosis progression in HIV mono-infected, but not in HIV/HCV co-infected, patients, likely reflecting the profound pathophysiological difference (metabolic vs. virus-induced) in the fibrogenetic process between the two clinical populations.

A broad range of HS prevalences have been reported in HIV mono-infection and HIV/HCV co-infection. Studies with low prevalence of HS (11–19%) had greater proportions of women and patients with abstinence or minimal alcohol intake.^{7,9} In contrast, studies reporting high prevalence of HS in HIV-infected patients (60–73%) included mostly male or patients who drank alcohol to excess.^{6,8} These studies were prone to selection bias since they assessed HS by liver biopsy or included only patients with elevated transaminases. Our reported prevalence of 36.1% HS in HIV mono-infection and 38.6% in HIV/HCV co-infection is in keeping with previous studies in HIV positive populations,

with low levels of alcohol excess and typical proportions of men (~70%), in Western countries.^{3,5,21} Moreover, these figures are higher than in the general Canadian population, where the prevalence of HS is 20–25%.²² Importantly, although previous studies suggested a higher prevalence of HS in HIV/HCV co-infected vs. HIV mono-infected patients, in our routine screening program we did not find such a difference. Instead, our data corroborates recent findings from Price *et al.*⁷ HS in HIV mono-infection can be induced by several postulated mechanisms, including direct viral effects on lipogenesis, long-standing exposure to ART, metabolic dysfunction and chronic inflammation.^{10,23} As for HIV/HCV co-infected patients, genotype 3 HCV infection is directly steatogenic,^{24,25} and HS improves with viral eradication.^{26,27} The mechanisms responsible for HS in non-genotype 3 HCV infection are related to metabolic factors, similarly to HIV mono-infection.^{28,29} Confirming the critical role of




Fig. 2. Prevalence of hepatic steatosis (HS) and liver fibrosis in the cross-sectional screening phase of the LIVEHIV Cohort (prevalence cohort) by HCV co-infection status. ***p* < 0.001. The *p* values refer to χ^2 test between HIV mono-infected and HIV/HCV co-infected patients.

metabolic dysfunction in inducing HS in the context of HIV infection, the main factors associated with prevalent HS were higher BMI and triglycerides. These were also independent predictors of the prevalence of significant liver fibrosis, together with other expected factors, namely HCV co-infection, longer time since HIV diagnosis and higher ALT. We and others found that BMI is the main predictor of prevalent HS in HIV-infected patients^{2,30} suggesting the importance of targeting normal weight. Another relevant finding of the cross-sectional phase of the LIVEHIV Cohort was that significant liver fibrosis and cirrhosis are very frequent

in consecutive HIV mono-infected patients undergoing a routine screening program. Our data confirm those from smaller studies in Western countries.^{2,4} This should raise awareness among clinicians of the emerging burden of liver disease in HIV mono-infected patients due to aging, metabolic dysfunction and associated fatty liver disease.

Surprisingly, HIV mono-infected individuals had significantly higher rates of HS progression than patients with HIV/HCV co-infection. Longitudinal studies assessing incidence rates of HS in the context of HIV infection are scarce, particularly for HIV mono-infected patients. In a study of 146 HIV/HCV co-infected patients with paired liver biopsies, progression to HS was observed in 40% of the patients over a median follow-up period of 3.3 (2.0–5.2) years, which is in line with our data.⁸ However, no prospective study assessed dynamics of HS in HIV mono-infected patients. The mechanistic explanation underlying our finding is likely multifactorial. HIV mono-infected patients had different clinical characteristics at baseline compared to HIV/HCV co-infected cases, particularly a higher frequency of metabolic dysfunction and a higher BMI, which was the strongest predictor of HS progression. Moreover, HIV/HCV co-infected patients had a different lipid profile than HIV mono-infected patients, including lower levels of total HDL and LDL cholesterol. The term “lipid paradox” has recently been coined for HIV/HCV co-infected patients, that is, despite the upregulation in HIV/HCV co-infection of proproteins which generally lead to higher serum LDL, LDL levels remain low in these patients.³¹ This is likely due to the profound chronic inflammatory state characterizing HIV/HCV co-infection, which may affect the ability of the liver to synthesize lipoproteins. Finally, given that liver fibrosis progresses faster in

Table 2. Multivariable analysis of factors associated with HS and significant liver fibrosis in the prevalence cohort (n = 726).

Variable	Any grade HS		Significant liver fibrosis	
	OR	aOR	OR	aOR
Age (per 10 years)	1.14 (0.96–1.34)	0.98 (0.71–1.35)	1.19 (1.02–1.39)*	1.03 (0.74–1.42)
Male gender (yes vs. no)	1.47 (0.96–2.26)		1.26 (0.86–1.84)	
Black ethnicity (yes vs. no)	0.51 (0.33–0.78)*	0.86 (0.42–1.77)	0.18 (0.11–0.31)**	0.48 (0.21–1.12)
MSM (yes vs. no)	1.26 (0.86–1.83)		0.83 (0.59–1.18)	
IDU (yes vs. no)	0.78 (0.35–1.74)		4.49 (2.89–6.99)**	
Diabetes (yes vs. no)	1.79 (1.19–2.69)*	1.60 (0.84–3.03)	1.11 (0.77–1.59)	
Hypertension (yes vs. no)	1.99 (1.26–3.14)*		1.03 (0.68–1.56)	
BMI (per Kg/m ²)	1.15 (1.09–1.21)**	1.16 (1.08–1.25)**	1.03 (0.99–1.06)	1.14 (1.07–1.21)**
HCV co-infection	1.11 (0.59–2.10)	0.54 (0.16–1.79)	8.01 (5.46–11.76)**	7.20 (3.67–14.12)**
Time since HIV diagnosis (per 10 years)	1.17 (0.94–1.47)	1.17 (0.75–1.80)	1.89 (1.52–2.36)**	2.30 (1.48–3.58)**
HIV viral load >40 cp/ml (yes vs. no)	1.10 (0.67–1.51)	0.93 (0.48–1.83)	0.98 (0.68–1.42)	1.87 (1.01–3.47)*
CD4 count (per cells/ μ l)	1.00 (0.99–1.00)		1.00 (0.99–1.00)	
Currently on PI (yes vs. no)	1.19 (0.83–1.72)		1.41 (1.03–1.92)*	1.41 (0.82–2.41)
Currently on NNRTI (yes vs. no)	0.76 (0.52–1.11)		0.68 (0.47–0.97)*	
Currently on NRTI (yes vs. no)	0.52 (0.34–0.81)*	0.41 (0.15–1.14)	0.63 (0.43–0.94)*	
Currently on Integrase inhibitor (yes vs. no)	1.17 (0.80–1.71)		0.84 (0.59–1.21)	
Platelets (per 10 ⁹ /L)	1.00 (0.99–1.00)		0.99 (0.98–0.99)**	
ALT (per 10 IU/L)	1.08 (1.01–1.15)*	1.08 (0.95–1.22)	1.32 (1.23–1.41)**	1.13 (1.04–1.24)*
HOMA-IR (per unit)	1.03 (0.94–1.13)		1.11 (1.04–1.18)*	
HDL cholesterol(per mmol/L)	0.33 (0.18–0.60)**		0.25 (0.15–0.44)**	
Triglycerides (per mmol/L)	1.39 (1.17–1.64)**	1.43 (1.09–1.89)*	1.24 (1.10–1.41)*	1.32 (1.07–1.64)*

Odds ratios (OR) and 95% confidence intervals are shown for each variable analyzed in univariable and multivariable logistic regression analysis. **p* < 0.05; ***p* < 0.001. HOMA-IR was evaluated in 335 patients.

ALT, alanine aminotransferase; BMI, body mass index; HCV, hepatitis C virus; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; HOMA-IR, homeostasis model for assessment of insulin resistance; HS, hepatic steatosis; IDU, injection drug use; IU, international unit; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; aOR, adjusted odds ratio; PI, protease inhibitor.

Research Article




Fig. 3. (A) Hepatic steatosis (HS) progression in the incidence cohort by HCV co-infection category (HIV mono-infection vs. HIV/HCV co-infection); (B) Liver fibrosis progression in HIV mono-infected patients by any grade HS category (present vs. absent). The p values refer to Log-rank test.

HIV/HCV co-infected patients, a slower HS progression could be partly explained by fat loss due to higher rates of advanced fibrosis.³² On multivariable analysis, BMI and HIV mono-infection were the only independent predictors of HS progression. The influence of BMI in HS dynamics measured by CAP has already been suggested by Macias and colleagues.²¹ However, the follow-up period was shorter than in our study and most of the included patients (74%) were HIV/HCV co-infected, so a direct

comparison with HIV mono-infected individuals was not carried out.

The longitudinal phase of the study on the LIVEHIV Cohort allowed us to characterize the influence of HS upon liver fibrosis. Three other studies reported incidence rates and predictors of liver fibrosis in HIV mono-infected patients. However, they all used simple serum biomarkers, which have inferior diagnostic accuracy than TE.¹⁸ Moreover, none of them reported the effect of HS on liver fibrosis progression.^{33–35} Our data demonstrate that HS and length of exposure to HIV are independent predictors of fibrosis progression in HIV mono-infection. In contrast, HS was not related to fibrosis progression in HIV/HCV co-infected patients. Viral-induced fibrogenesis and necroinflammation had the major impact in this setting, as demonstrated by the fact that detectable HCV RNA and elevated ALT were predictive of fibrosis progression. This is in keeping with previous data demonstrating that steatohepatitis, but not HS, and necroinflammation are associated with fibrosis progression in HIV/HCV co-infected patients.⁸ Indeed, HIV/HCV patients derive the greatest benefit from HCV eradication with antiviral therapy.^{26,27}

Our study has several strengths. To our knowledge, it is the first prospective study that captures the dynamics of HS and demonstrates its association with fibrosis progression in HIV mono-infected patients. Moreover, we included only consecutive patients as part of an ongoing screening program at our center. This study design minimizes the risk of selection bias, which may have occurred in previous studies selecting patients with elevated transaminases.

Several limitations of our study must be acknowledged. First, we did not include controls from the general Canadian population for a direct comparison. Second, we did not include histology or MRI spectroscopy to confirm HS. However, it would not be justifiable to screen an asymptomatic population with liver biopsy. MRI spectroscopy is unsuitable for screening large cohorts and is not recommended for routine clinical use.³⁶ Third, TE may overestimate fibrosis in the setting of severe HS.³⁷ However, following correction of the small number of cases at risk of inaccuracy, there was no change in our results (data not shown). On the same line, when we perform the adjustments to CAP values suggested by Karlas *et al.*, the median CAP did not change significantly and only 6% of the whole cohort increased or decreased HS grade.¹⁶ Fourth, due to the relatively short follow-up period, we were not able to study the influence of specific ART drugs on HS and liver fibrosis. Finally, we could not identify those patients with non-alcoholic steatohepatitis, which is the evolutionary counterpart of HS. Accurate non-invasive methods capable

Table 3. Multivariable analysis of predictors of HS progression in the incidence cohort after exclusion of 81 patients with severe HS at baseline.

Variable	Unadjusted HR	aHR
Age (per 10 years)	1.06 (0.86–1.31)	1.12 (0.84–1.50)
Black ethnicity (yes vs. no)	1.36 (0.82–2.23)	1.08 (0.54–2.16)
BMI (per Kg/m ²)	1.09 (1.04–1.14)**	1.09 (1.03–1.17)*
Time since HIV diagnosis (per 10 years)	1.01 (0.86–1.18)	1.16 (0.99–1.37)
HCV co-infection (yes vs. no)	0.55 (0.36–0.85)*	0.51 (0.27–0.96)*
HIV viral load >40 cp/ml (yes vs. no)	1.00 (0.57–1.77)	1.07 (0.51–2.27)
ALT (per 10 IU/L)	1.01 (0.96–1.06)	1.04 (0.97–1.11)
Triglycerides (per mmol/L)	1.17 (1.02–1.33)*	1.15 (0.96–1.38)
Baseline CAP (per 10 dB/m)	1.08 (1.03–1.14)*	1.03 (0.97–1.10)

Hazard ratios (HR) and 95% confidence intervals are shown for each variable analyzed in multivariable Cox regression analysis. * $p < 0.05$; ** $p < 0.001$.

ALT, alanine aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; dB/m, decibel/meter; HIV, human immunodeficiency virus; HCV, hepatitis C virus; aHR, adjusted hazard ratio; IU, international unit.

Table 4. Multivariable analysis of predictors of liver fibrosis progression by HCV co-infection status in the incidence cohort after exclusion of 39 patients with cirrhosis at baseline.

Variable	Unadjusted HR	aHR
HIV mono-infected		
Black ethnicity (yes vs. no)	0.58 (0.19–1.76)	0.90 (0.22–3.70)
BMI (per Kg/m ²)	1.03 (0.92–1.15)	0.96 (0.84–1.09)
Time since HIV diagnosis (per 10 years)	1.52 (1.29–1.78)**	1.43 (1.02–2.12)*
HIV viral load >40 cp/ml (yes vs. no)	1.72 (0.51–5.86)	1.31 (0.30–5.69)
ALT (per 10 IU/L)	1.02 (1.01–1.03)*	1.20 (0.96–1.47)
Any grade HS (yes vs. no)	3.90 (1.62–9.37)*	4.18 (1.21–14.5)*
HCV co-infected		
Time since HIV diagnosis (per 10 years)	0.64 (0.31–1.33)	0.85 (0.42–1.74)
HIV viral load <40 cp/ml (yes vs. no)	1.99 (0.66–6.00)	1.89 (0.57–6.25)
Detectable HCV RNA (yes vs. no)	11.3 (2.51–50.8)*	5.98 (1.28–27.9)*
ALT (per 10 IU/L)	1.01 (1.00–1.01)**	1.05 (1.00–1.09)*
Any grade HS (yes vs. no)	0.51 (0.17–1.54)	0.79 (0.22–2.81)

Hazard ratios (HR) and 95% confidence intervals are shown for each variable analyzed in multivariable Cox regression analysis. **p* <0.05; ***p* <0.001. HS, hepatic steatosis; ALT, alanine aminotransferase; BMI, body mass index; HCV, hepatitis C virus; HIV, human immunodeficiency virus; aHR, adjusted hazard ratio; IU, international unit.

of diagnosing non-alcoholic steatohepatitis are still lacking, and this should be a focus for future research.

In summary, this study demonstrates that HS is a frequent comorbidity in HIV-infected patients. HIV mono-infected patients have faster HS progression than HIV/HCV co-infected patients. In HIV mono-infected, but not HIV/HCV co-infected, patients HS is associated with fibrosis progression. Those with a higher BMI are at particularly high risk of HS progression and should be targeted for potential interventions. Further long-term studies to evaluate the effect of HS and liver fibrosis on clinical outcomes are warranted.

Financial support

ViiV and Merck provided a grant to establish the diagnostic center for hepatic fibrosis and steatosis at McGill University Health Centre.

TP holds a Starter Grant for Clinical Lecturers from the Academy of Medical Sciences/ Wellcome Trust (UK) and a Canadian Association of the Study of the Liver Clinical Hepatology Fellowship. GS and BL hold a *Chercheur-Boursier* career award from the *Fonds de recherche du Québec – Santé* (FRQ-S). MBK holds a *Chercheurs Nationaux* career award from the FRQ-S. Part of this work has been presented at the Liver Meeting of the American Association for the Study of Liver Diseases 2016.

Conflict of interest

BL has acted as a consultant for ViiV, Gilead, and Merck and received research funding from Merck, Gilead and Abbvie. MD has served as an advisory board member for Merck, Janssen, Gilead. PW has acted as consultant for BMS, Gilead, Merck, Novartis. PG has acted as consultant for Merck and Gilead. MBK has acted as a consultant for ViiV, Gilead, Janssen and Merck and received research funding from Merck and ViiV. GS has acted as speaker for Merck, BMS, Gilead, Abbvie, served as an advisory board member for Merck and BMS and has received research funding from Merck.

TP, AB, MS, AH, EVL, CP have nothing to disclose.

Authors contributions

TP contributed to study design, data, interpretation of the data and first draft of the article. BL, MS, PG, PW, MD, AH and EVL contributed to data and interpretation of data. AB and CP contributed to data. MBK contributed to conception, study design, data and interpretation of the data. GS contributed to conception, study design, data and interpretation of the data, statistical analysis and first draft of the manuscript. All authors approved the final version of the article.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.jhep.2017.05.011>.

References

- Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med* 2002;346:1221–1231.
- Vuille-Lessard E, Lebouche B, Lennox L, Routy JP, Costiniuk CT, Pexos C, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. *AIDS* 2016;30:2635–2643.
- Guaraldi G, Squillace N, Stentarelli C, Orlando G, D’Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis* 2008;47:250–257.
- Lombardi R, Sambatakou H, Mariolis I, Cokkinos D, Papatheodoridis GV, Tsochatzis EA. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. *Dig Liver Dis* 2016;48:1471–1477.
- Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, et al. Nonalcoholic fatty liver disease among HIV-infected persons. *J Acquir Immune Defic Syndr* 2009;50:464–473.
- Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. *Clin Infect Dis* 2015;60:1569–1578.
- Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, et al. HIV-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. *Hepatology* 2017;65:853–863.

Research Article

- [8] Macias J, Berenguer J, Japon MA, Giron-Gonzalez JA, Rivero A, Lopez-Cortes LF, et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. *Hepatology* 2012;56:1261–1270.
- [9] Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, et al. Incidence and risk factors for steatosis progression in adults coinfecting with HIV and hepatitis C virus. *Gastroenterology* 2011;140:809–817.
- [10] Kuller LH, Tracy R, Bellosso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. *PLoS Med* 2008;5 e203.
- [11] Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. *J Hepatol* 2006;44:1167–1174.
- [12] Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD American Association for the Study of Liver Diseases. Liver biopsy. *Hepatology* 2009;49:1017–1044.
- [13] Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Mullhaupt B, et al. Progression of liver fibrosis in HIV/HCV co-infection: a comparison between non-invasive assessment methods and liver biopsy. *PLoS One* 2015;10 e0138838.
- [14] Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. *Audit. The Alcohol Use Disorders Identification Test (AUDIT): Guidelines for use in primary care*; 2001.
- [15] Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. *Ultrasound Med Biol* 2010;36:1825–1835.
- [16] Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. *J Hepatol* 2017;66:1022–1030.
- [17] Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005;128:343–350.
- [18] Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. *Gastroenterology* 2012;142:1293–1302 e1294.
- [19] Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. *Hepatology* 2012;55:199–208.
- [20] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412–419.
- [21] Macias J, Real LM, Rivero-Juarez A, Merchante N, Camacho A, Neukam K, et al. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. *HIV Med* 2016;17:766–773.
- [22] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011;34:274–285.
- [23] Lemoine M, Barbu V, Girard PM, Kim M, Bastard JP, Wendum D, et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. *AIDS* 2006;20:387–395.
- [24] Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. *J Hepatol* 2000;33:106–115.
- [25] Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. *J Hepatol* 2007;46:999–1008.
- [26] Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. *Gut* 2004;53:420–424.
- [27] Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. *J Hepatol* 2004;40:484–490.
- [28] Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. *World J Gastroenterol* 2014;20:7089–7103.
- [29] White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. *J Hepatol* 2008;49:831–844.
- [30] Macias J, Gonzalez J, Tural C, Ortega-Gonzalez E, Pulido F, Rubio R, et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. *AIDS* 2014;28:1279–1287.
- [31] Kohli P, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, et al. HIV and Hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): an apparent “PCSK9-Lipid Paradox”. *J Am Heart Assoc* 2016;5.
- [32] van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? *Hepatology* 2013;57:2180–2188.
- [33] Mendeni M, Foca E, Gotti D, Ladisa N, Angarano G, Albini L, et al. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. *Clin Infect Dis* 2011;52:1164–1173.
- [34] Sebastiani G, Rollet-Kurhajec KC, Pexos C, Gilmore N, Klein MB. Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. *Open Forum Infect Dis* 2015;2:ofv015.
- [35] Kim HN, Nance R, Van Rompaey S, Delaney JC, Crane HM, Cachay ER, et al. Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. *J Acquir Immune Defic Syndr* 2016;72:437–443.
- [36] European Association for the Study of the Liver/European Association for the Study of Diabetes (EASD)/European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016;64:1388–1402.
- [37] Petta S, Wai-Sun Wong V, Camma C, Hiriart JB, Wong GL, Marra F, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. *Hepatology* 2017;65:1145–1155.